ProQR Therapeutics (PRQR) EBITDA Margin (2013 - 2026)
ProQR Therapeutics (PRQR) posted quarterly EBITDA Margin of 671.37% for Q1 2026, down 43203.0% year-on-year from N/an in Q1 2025, and down 245.98% on a QoQ basis from 194.05% in Q4 2025.
ProQR Therapeutics (PRQR) EBITDA Margin (2013 - 2026) Analysis & Trends
ProQR Therapeutics (PRQR) has reported EBITDA Margin for 14 consecutive years, with 671.37% the latest figure, recorded in Q1 2026.
- Quarterly EBITDA Margin fell 43203.0% year-over-year to 671.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 344.85% (down 16981.0% YoY) and the FY2025 annual result came in at 273.14%, down 11196.0% from the prior year.
- EBITDA Margin fell to 671.37% in Q1 2026 per PRQR's latest filing, from 194.05% in the prior quarter.
- Over the last five years, EBITDA Margin for PRQR reached as high as 57.1% in Q2 2024 and fell as low as 2435.26% in Q3 2022.
- A 5-year average of 752.24% and a median of 391.53% in 2025 frame the typical range for EBITDA Margin.
- The largest YoY upside for EBITDA Margin was 551965 bps in 2022 against a maximum downside of 140832 bps in 2022.
- Year by year, EBITDA Margin stood at 1730.56% in 2022, then soared by 89 bps to 190.86% in 2023, then decreased by 23 bps to 234.06% in 2024, then rose by 17 bps to 194.05% in 2025, then sank by 246 bps to 671.37% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 671.37%, 194.05%, and 391.53% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ProQR Therapeutics | 219.53 Mn | 175.72 Mn | - | -671.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -671.37% |
| Dec 31, 2025 | -194.05% |
| Sep 30, 2025 | -391.53% |
| Jun 30, 2025 | -320.91% |
| Mar 31, 2025 | -239.34% |
| Dec 31, 2024 | -234.06% |
| Sep 30, 2024 | -226.80% |
| Jun 30, 2024 | -57.10% |
| Mar 31, 2024 | -181.46% |
| Dec 31, 2023 | -190.86% |
| Sep 30, 2023 | -539.49% |
| Jun 30, 2023 | -731.20% |
| Mar 31, 2023 | -1,433.44% |
| Dec 31, 2022 | -1,730.56% |
| Sep 30, 2022 | -2,435.26% |
| Jun 30, 2022 | -1,702.37% |
| Mar 31, 2022 | -1,508.32% |
| Dec 31, 2021 | -7,250.21% |
| Sep 30, 2021 | -1,669.38% |
| Jun 30, 2021 | -5,433.33% |